The Food and Drug Administration (FDA) issued a warning to EPH Technologies, Inc. They determined that their products, Detoxoplex, Sinoplex and Migrenza are unapproved new drugs sold in violation of the Federal Food, Drug, and Cosmetic Act (FD&C) and other federal laws.
EPH Technologies markets Detoxoplex for the treatment or cure of opioid withdrawal symptoms. However, this product has not been determined by the FDA to be safe and effective for these uses. Further, this treatment could cause patients to forgo or delay FDA-approved treatments for opioid addiction and withdrawal. The marketing and sale of unapproved opioid addiction treatment products poses a significant threat to the public health. They also claim that Sinoplex reduces symptoms commonly associated with allergies, congestion, nausea, migraines, headache, hangover, colds and dizziness. In addition, their website states Migrenza assists in reducing headaches, migraines, congestion and hangovers.
Claims on their website, www.ephbiotech.com and/or product labels establish that their products are drugs as defined by federal law because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, including opiate withdrawal, and/or because they are intended to affect the structure or function of the body. Introducing or delivering these products for introduction into interstate commerce for such uses violates the FD&C Act. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from the FDA.
If you have bought any EPH Technologies products, you could be at risk. Please contact us immediately to discuss your legal options. The attorneys at Finkelstein, Blankinship, Frei-Pearson & Garber, LLP have successfully prosecuted numerous consumer protection actions and we look forward to discussing your case.